Clopidogrel-Wirksamkeit
Clopidogrel response
General description
Arterial thromboembolism is a common and severe complication in cats with cardiac disease and is most often prevented with clopidogrel therapy. However, not all cats respond equally to this treatment, indicating the presence of clopidogrel resistance. A genetic variant of the P2RY1 gene has been significantly associated with this resistance and means that cats carrying the variant may require alternative or additional thromboprophylactic treatment.
Order details
| Test number | 8974 |
| Sample material | 0.5 ml EDTA blood, 2x cheek swab, 1x special swab (eNAT) |
| Test duration | 7-14 working days |
Test specifications
| Symptom complex | metabolic |
| Inheritance | complex |
| Gene | P2RY1 |
| Mutation | G-A |
| Literature | OMIA:002421-9685 |
Detailed description
Arterial thromboembolism (ATE) is a common complication associated with high morbidity and mortality in cats with hypertrophic cardiomyopathy (HCM) or other cardiac diseases. ATE is a severe medical condition in which a blood clot (thrombus) forms within an artery, obstructing blood flow to vital organs or limbs and often resulting in tissue damage or infarction.
To prevent ATE in affected cats, clopidogrel is commonly used as an antiplatelet medication that irreversibly inhibits platelet activation by blocking platelet adenosine diphosphate (ADP) receptors. However, substantial interpatient variability in response to clopidogrel therapy has been reported, suggesting the presence of clopidogrel resistance.
A genetic variant of the P2RY1 gene, which encodes one of the ADP receptors (P2RY1), has been identified as being significantly associated with clopidogrel resistance. This variant alters the response to clopidogrel, indicating that cats carrying the P2RY1 variant may require alternative or additional thromboprophylactic treatment.
